BGBIO Stock Overview
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases.
Price History & Performance
|Historical stock prices|
|Current Share Price||kr16.63|
|52 Week High||kr27.92|
|52 Week Low||kr13.79|
|1 Month Change||-13.02%|
|3 Month Change||1.65%|
|1 Year Change||-31.05%|
|3 Year Change||-26.42%|
|5 Year Change||-26.09%|
|Change since IPO||-33.48%|
Recent News & Updates
Is BerGenBio (OB:BGBIO) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
|BGBIO||NO Biotechs||NO Market|
Return vs Industry: BGBIO exceeded the Norwegian Biotechs industry which returned -47.8% over the past year.
Return vs Market: BGBIO underperformed the Norwegian Market which returned 12.3% over the past year.
|BGBIO Average Weekly Movement||7.5%|
|Biotechs Industry Average Movement||8.3%|
|Market Average Movement||7.5%|
|10% most volatile stocks in NO Market||13.0%|
|10% least volatile stocks in NO Market||4.3%|
Stable Share Price: BGBIO is not significantly more volatile than the rest of Norwegian stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: BGBIO's weekly volatility (8%) has been stable over the past year.
About the Company
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. Its Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19.
BerGenBio Fundamentals Summary
|BGBIO fundamental statistics|
Is BGBIO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BGBIO income statement (TTM)|
|Cost of Revenue||kr0|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
May 24, 2022
|Earnings per share (EPS)||-3.49|
|Net Profit Margin||-39,969.51%|
How did BGBIO perform over the long term?See historical performance and comparison
Is BerGenBio undervalued compared to its fair value and its price relative to the market?
Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate BGBIO's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate BGBIO's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: BGBIO is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.
PE vs Market: BGBIO is unprofitable, so we can't compare its PE Ratio to the Norwegian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BGBIO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BGBIO is good value based on its PB Ratio (3.8x) compared to the NO Biotechs industry average (4x).
How is BerGenBio forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BGBIO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BGBIO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BGBIO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BGBIO's revenue (43.7% per year) is forecast to grow faster than the Norwegian market (1% per year).
High Growth Revenue: BGBIO's revenue (43.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BGBIO is forecast to be unprofitable in 3 years.
How has BerGenBio performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BGBIO is currently unprofitable.
Growing Profit Margin: BGBIO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BGBIO is unprofitable, and losses have increased over the past 5 years at a rate of 15.5% per year.
Accelerating Growth: Unable to compare BGBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BGBIO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).
Return on Equity
High ROE: BGBIO has a negative Return on Equity (-80.47%), as it is currently unprofitable.
How is BerGenBio's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: BGBIO's short term assets (NOK449.0M) exceed its short term liabilities (NOK64.9M).
Long Term Liabilities: BGBIO's short term assets (NOK449.0M) exceed its long term liabilities (NOK942.0K).
Debt to Equity History and Analysis
Debt Level: BGBIO is debt free.
Reducing Debt: BGBIO had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BGBIO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: BGBIO has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 16.6% each year.
What is BerGenBio current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BGBIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BGBIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BGBIO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BGBIO's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as BGBIO has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Martin Olin (52 yo)
Mr. Martin Olin serves as Chief Executive Officer at BerGenBio ASA since September 8, 2021. Mr. Olin has been Chairman of the Board at AcouSort AB (publ) since April 28, 2021. He has experience from execut...
CEO Compensation Analysis
Compensation vs Market: Martin's total compensation ($USD399.09K) is about average for companies of similar size in the Norwegian market ($USD497.55K).
Compensation vs Earnings: Insufficient data to compare Martin's compensation with company performance.
Experienced Management: BGBIO's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Experienced Board: BGBIO's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
BerGenBio ASA's employee growth, exchange listings and data sources
- Name: BerGenBio ASA
- Ticker: BGBIO
- Exchange: OB
- Founded: 2007
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: kr1.474b
- Shares outstanding: 88.66m
- Website: https://www.bergenbio.com
Number of Employees
- BerGenBio ASA
- Jonas Lies vei 91
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/22 00:00|
|End of Day Share Price||2022/05/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.